Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (411-420 of 529) with videos related to

Pageof 53
Sort By:
Journal of Clinical Medicine|January 21, 2023
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung CancerSravani Ramisetty, Prakash Kulkarni, Supriyo Bhattacharya, et al.
Trends in Cancer|January 12, 2023
Addressing the genetic/nongenetic duality in cancer with systems biologyPrakash Kulkarni, H Steven Wiley, Herbert Levine, et al.
Head & Neck|March 20, 2023
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancerKourtney L Kostecki, Mari Iida, Anne L Wiley, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2013
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancerAnne M Traynor, Tracey L Weigel, Kurt R Oettel, et al.
International Journal of Molecular Sciences|May 25, 2024
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast CancerMari Iida, Bridget E Crossman, Kourtney L Kostecki, et al.
Scientific Reports|April 16, 2016
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesotheliomaFrances E Lennon, Gianguido C Cianci, Rajani Kanteti, et al.
Frontiers in Oncology|March 2, 2023
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapyMichael R Sayer, Isa Mambetsariev, Kun-Han Lu, et al.
BMC Cancer|June 14, 2012
The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridizationFang-Yi Lo, Jer-Wei Chang, I-Shou Chang, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)Suresh S Ramalingam, Angela M Davies, Jeffrey Longmate, et al.
Pageof 53

Showing results (411-420 of 529) with videos related to

Sort By:
Pageof 53
Journal of Clinical Medicine|January 21, 2023
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung CancerSravani Ramisetty, Prakash Kulkarni, Supriyo Bhattacharya, et al.
Trends in Cancer|January 12, 2023
Addressing the genetic/nongenetic duality in cancer with systems biologyPrakash Kulkarni, H Steven Wiley, Herbert Levine, et al.
Head & Neck|March 20, 2023
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancerKourtney L Kostecki, Mari Iida, Anne L Wiley, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2013
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancerAnne M Traynor, Tracey L Weigel, Kurt R Oettel, et al.
International Journal of Molecular Sciences|May 25, 2024
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast CancerMari Iida, Bridget E Crossman, Kourtney L Kostecki, et al.
Scientific Reports|April 16, 2016
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesotheliomaFrances E Lennon, Gianguido C Cianci, Rajani Kanteti, et al.
Frontiers in Oncology|March 2, 2023
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapyMichael R Sayer, Isa Mambetsariev, Kun-Han Lu, et al.
BMC Cancer|June 14, 2012
The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridizationFang-Yi Lo, Jer-Wei Chang, I-Shou Chang, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)Suresh S Ramalingam, Angela M Davies, Jeffrey Longmate, et al.
Pageof 53